Issues
-
Cover Image
Cover Image
About the Cover
Cytotoxic T cells rely on a complex system of checks and balances that modulates their activation, functional capabilities, and survival. One surface protein, SLAMF6, binds to itself in a homotypic fashion. Eisenberg and colleagues created a reagent from the ectodomain of SLAMF6 that interfered with this binding, resulting in increased activation of CD8+ T cells and stronger effector functions, even prolonging the survival in vivo of adoptively transferred CD8+ T cells, without the addition of IL2. This work provides evidence that when SLAMF6 is engaged via cell–cell contact it has an inhibitory effect on CD8+ T cells, which is relieved by the competitive binding of its soluble form. Read more in this issue, starting on page 127. The original confocal image is of human T cells activated with anti-CD3, with SLAMF6 (red) clustering at sites of cell–cell contact. Artwork by Lewis Long. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Immunology Research
Cancer Immunology Research, launched in 2013 with Glenn Dranoff as founding Editor-in-Chief, is published by the AACR. The Journal illuminates the interplay between tumors and the immune system, with Robert D. Schreiber and Philip D. Greenberg serving as the Editors-in-Chief.
Table of Contents
Highlights from the Literature
Meeting Report
Research Articles
Soluble SLAMF6 Receptor Induces Strong CD8+ T-cell Effector Function and Improves Anti-Melanoma Activity In Vivo
TUSC2 Immunogene Therapy Synergizes with Anti–PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic Kras-Mutant Mouse Lung Cancer Models
Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade
Antigen-Specific Antitumor Responses Induced by OX40 Agonist Are Enhanced by the IDO Inhibitor Indoximod
The Immune Checkpoint Modulator OX40 and Its Ligand OX40L in NK-Cell Immunosurveillance and Acute Myeloid Leukemia
T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma—Implications for Adoptive Cell Therapy
Journal Archive
Cancer Immunology Research
(2013-Present)Published monthly since 2013.
(ISSN 2326-6066)
Cancer Immunity
(2001-2013; volumes 1-13)Published periodically from 2001-2013.
(EISSN 1424-9634)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.